Clinical trial · Observational
Construction of Diagnosis and Treatment System for Primary Vitreoretinal Lymphoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study intends to apply for the establishment of research beds, establish a Chinese PVRL research cohort, and carry out a to achieve the following research objectives: The goal of this prospective observational study is to construct the diagnosis and treatment system for primary vitreoretinal lymphoma（PVRL）. The study is to achieve the following research objectives: 1. To establish a comprehensive diagnostic criteria for PVRL with high diagnostic efficiency and strengthen the PVRL diagnostic system; 2. To establish a standardized treatment pathway for PVRL and evaluate the efficacy and safety of treatment; 3. To screen the prognosis evaluation indicators, and to establish the follow-up process and prognosis evaluation system of PVRL； 4. To explore the pathogenesis of PVRL, specific tumor markers and drug therapeutic targets.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Primary Vitreoretinal Lymphoma | Primary Vitreoretinal Non-Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Intravitreal injection of methotrexate | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Group A
- description
- Cerebrospinal fluid IL-10 was normal
- interventionNames
- Drug: Intravitreal injection of methotrexate
- label
- Group B
- description
- Cerebrospinal fluid IL-10 was normal or elevated
- interventionNames
- Drug: Intravitreal injection of methotrexate
Primary outcomes (2)
- measure
- Interleukin-10/Interleukin-6（IL-10/IL-6）
- timeFrame
- 1 year
- description
- aqueous fluid
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Newly diagnosed PVRL patients admitted to the Ophthalmology or Hematology departments of Peking Union Medical College Hospital from 2022 to 2024; * 18-75 years old; * The diagnosis was confirmed by pathology, aqueous humor/vitreous IL-10/IL-6, vitreous flow cytometry and gene rearrangement.; * HIV-Ab negative; * Creatinine clearance \> 50ml/min; * Sign informed consent. Exclusion Criteria: * Combined with other tumors; * Uncontrolled active infections; * Pregnant or lactating women; * Antitumor therapy other than the protocol of this study was used.
References
Publications (0)
Data not yet available